| [25] |
Gennari L, Merlotti D, Valleggi F, et al. Selective estrogen receptor modulators for postmenopausal osteoporosis: current state of development[J]. Drugs Aging,2007,24(5):361-379.
|
| [26] |
Gu R, Jia W, Zeng Y, et al. A comparison of survival outcomes and side effects of toremifene or tamoxifen therapy in premenopausal estrogen and progesterone receptor positive breast cancer patients: a retrospective cohort study[J]. BMC Cancer,2012,12:161.
|
| [27] |
Erkkola R, Mattila L, Powles T, et al. Bone mineral density and lipid changes during 5 years of follow-up in a study of prevention of breast cancer with toremifene in healthy,high-risk pre- and post-menopausal women [J]. Breast Cancer Res Treat,2005,93(3):277-287.
|
| [28] |
Braithwaite RS,Chlebowski RT,Lau J, et al. Meta-analysis of vascular and neoplastic events associated with tamoxifen[J]. J Gen Intern Med,2003,18(11):937-947.
|
| [29] |
Sasaki H,Nishii H,Takahashi H,et al. Mutation of the Ki-ras protooncogene in human endometrial hyperplasia and carcinoma[J]. Cancer Res,1993,53(8):1906-1910.
|
| [30] |
Deligdisch L. Effects of hormone therapy on the endometrium[J]. Mod Pathol,1993,6(1):94-106.
|
| [31] |
Wallén M, Tomás E, Visakorpi T, et al. Endometrial K-ras mutations in postmenopausal breast cancer patients treated with adjuvant tamoxifen or toremifene [ J]. Cancer Chemother Pharmacol,2005,55(4):343-346.
|
| [32] |
Niwa K, Hashimoto M, Lian Z, et al. Inhibitory effects of toremifene on N-methyl-N-nitrosourea and estradiol-17betainduced endometrial carcinogenesis in mice[J]. Jpn J Cancer Res,2002,93(6):626-635.
|
| [33] |
Tominaga T, Kimijima I, Kimura M, et al. Effects of toremifene and tamoxifen on lipid profiles in post-menopausal patients with early breast cancer: interim results from a Japanese phase Ⅲtrial[J]. Jpn J Clin Oncol,2010,40(7):627-633.
|
| [34] |
Kimura M, Tominaga T, Kimijima I, et al. Phase Ⅲrandomized trial of toremifene versus tamoxifen for Japanese postmenopausal patients with early breast cancer[EB/OL].[2013-01-02]. http:/ /link. springer. com/article/10.1007%2Fs12282-012-0394-6#page-1.
|
| [35] |
Rugo HS. The breast cancer continuum in hormone-receptorpositive breast cancer in postmenopausal women: evolving management options focusing on aromatase inhibitors[J]. Ann Oncol,2008,19(1):16-27.
|
| [36] |
Colleoni M, Gelber S, Coates AS, et al. Influence of endocrine-related factors on response to perioperative chemotherapy for patients with node-negative breast cancer[J].J Clin Oncol,2001,19(21):4141-4149.
|
| [37] |
Yamamoto Y, Masuda N, Ohtake T, et al. Clinical usefulness of high-dose toremifene in patients relapsed on treatment with an aromatase inhibitor[J]. Breast Cancer,2010,17(4):254-260.
|
| [38] |
Sawaki M, Wada M, Sato Y, et al. High-dose toremifene as first-line treatment of metastatic breast cancer resistant to adjuvant aromatase inhibitor: A multicenter phase Ⅱ study[J]. Oncol Lett,2012,3(1):61-65.
|
| [39] |
Okita A, Saeki T, Aogi K, et al. Efficacy and tolerability of weekly paclitaxel in combination with high-dose toremifene citrate in patients with metastatic breast cancer[J]. Acta Med Okayama,2009,63(4):187-194.
|
| [1] |
Early Breast Cancer Trialists’ Collaborative Group (EBCTCG).Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials[J]. Lancet,2005,365(9472):1687-1717.
|
| [2] |
Osborne CK. Tamoxifen in the treatment of breast cancer[J].N Engl J Med,1998,339(22):1609-1618.
|
| [3] |
Pyrhönen S, Ellmén J, Vuorinen J, et al. Meta-analysis of trials comparing toremifene with tamoxifen and factors predicting outcome of antiestrogen therapy in postmenopausal women with breast cancer[J]. Breast Cancer Res Treat, 1999, 56(2):133-143.
|
| [4] |
Zhou WB, Ding Q, Chen L, et al. Toremifene is an effective and safe alternative to tamoxifen in adjuvant endocrine therapy for breast cancer: results of four randomized trials[J]. Breast Cancer Res Treat,2011,128(3):625-631.
|
| [5] |
Gennari L, Merlotti D, Stolakis K, et al. Pharmacokinetic evaluation of toremifene and its clinical implications for the treatment of osteoporosis[J]. Expert Opin Drug Metab Toxicol,2012,8(4):505-513.
|
| [6] |
Lewis JD, Chagpar AB, Shaughnessy EA, et al. Excellent outcomes with adjuvant toremifene or tamoxifen in early stage breast cancer[J]. Cancer,2010,116(10):2307-2315.
|
| [7] |
Kusama M, Miyauchi K, Aoyama H, et al. Effects of toremifene(TOR) and tamoxifen(TAM) on serum lipids inpost menopausal patients with breast cancer [J]. Breast Cancer Res Treat,2004,88(1):1-8.
|
| [8] |
Wärri AM, Huovinen RL, Laine AM, et al. Apoptosis in toremifene-induced growth inhibition of human breast cancer cells in vivo and in vitro[J]. J Natl Cancer Inst,1993,85(17):1412-1418.
|
| [9] |
Gershanovich M, Garin A, Baltina D, et al. A phase Ⅲcomparison of two toremifene doses to tamoxifen in postmenopausal women with advanced breast cancer. Eastern European Study Group[J]. Breast Cancer Res Treat,1997,45(3):251-262.
|
| [10] |
Hirsimäki P, Aaltonen A. Toxicity of antiestrogens[J]. Breast J,2002,8(2):92-96.
|
| [11] |
Davies EL, Gateley CA, Miers M, et al. The long-term course of mastalgia[J]. J R Soc Med,1998,91(9):462-464.
|
| [12] |
Ader DN, Shriver CD. Cyclical mastalgia: prevalence and impact in an outpatient breast clinic sample[J]. J Am Coll Surg,1997,185(5):466-470.
|
| [13] |
Ader DN, Browne MW. Prevalence and impact of cyclic mastalgia in a United States clinic-based sample[J]. Am J Obstet Gynecol,1997,177(1):126-132.
|
| [14] |
Hindle WH. Breast care:a clinical guidebook for women’s primary health care providers[M]. New York: Springer,1999:152-165.
|
| [15] |
Smith RL,Pruthi S, Fitzpatrick LA. Evaluation and management of breast pain[J]. Mayo Clin Proc,2004,79(3):353-372.
|
| [16] |
Kontostolis E, Stefanidis K, Navrozoglou I, et al. Comparison of tamoxifen with danazol for treatment of cyclical mastalgia[J]. Gynecol Endocrinol,1997,11(6):393-397.
|
| [17] |
Millet AV, Dirbas FM. Clinical management of breast pain: a review[J]. Obstet Gynecol Surv,2002,57(7):451-461.
|
| [18] |
Duffy S,Jackson TL,Lansdown M. et al. The ATAC(‘Arimidex’,Tamoxifen, Alone or in Combination) adjuvant breast cancer trial:baseline endometrial sub-protocol data on the effectiveness of transvaginal ultrasonography and diagnostic hysteroscopy[J].Hum Reprod,2005,20(1):294-301.
|
| [19] |
Braithwaite RC,Chlebowski RT,Lau J,et al. Meta-analysis of vascular and neoplastic events associated with tamoxifen[J]. J Gen Intern Med,2003,18(11):937-947.
|
| [20] |
Marttunen MB, Cacciatore B, Hietanen P, et al. Prospective study on gynaecological effects of two antioestrogens tamoxifen and toremifene in postmenopausal women[J]. Br J Cancer,2001,84(7):897-902.
|
| [21] |
Oksa S, Luukkaala T, Mäenpää J. Toremifene for premenstrual mastalgia: a randomised, placebo-controlled crossover study[J]. BJOG,2006,113(6):713-718.
|
| [22] |
Oksa S, Luukkaala T, Mäenpää JU. Toremifene use does not alter serum inhibin A and B levels during mid-luteal phase in women with premenstrual mastalgia[J]. Gynecol Endocrinol,2010,26(2):114-117.
|
| [23] |
Gong C, Song E, Jia W, et al. A double-blind randomized controlled trial of toremifene therapy for mastalgia[J]. Arch Surg,2006,141(1):43-47.
|
| [24] |
Goldhirsch A, Ingle JN, Gelber RD, et al. Thresholds for therapies: highlights of the St Gallen International Expert Consensus on the primary therapy of early breast cancer 2009[J]. Ann Oncol,2009,20(8):1319-1329.
|